Reven Oncology Licensing

Reven Oncology is a clinical-stage biopharmaceutical company focused on the development of its proprietary multi-component small molecule platform, RJX (Rejuvenox). The RJX technology is designed to manage reactive oxygen species and modulate systemic inflammation by downregulating pro-inflammatory cytokines. The company's lead oncology program is evaluating RJX in combination with gemcitabine and Abraxane for the treatment of metastatic pancreatic cancer. Beyond oncology, Reven is advancing clinical trials for RJX in critical care indications, including sepsis and ARDS, as well as in vascular conditions such as peripheral arterial disease.